Becton, Dickinson and Co. (BDX), a prominent medical technology company, reported its third-quarter financial results on Thursday and updated its fiscal 2024 outlook. The company increased its adjusted earnings guidance but slightly lowered its annual revenue forecast.
For fiscal 2024, Becton, Dickinson now anticipates adjusted earnings between $13.05 and $13.15 per share. The company expects revenues to grow by approximately 3.7 percent, reaching around $20.1 billion, with adjusted revenues projected between $20.1 billion and $20.2 billion. Organic revenue growth is forecasted to be between 5.0 and 5.25 percent.
This revision comes after the company's previous prediction of adjusted earnings ranging from $12.95 to $13.15 per share. The earlier revenue expectations were between $20.1 billion and $20.3 billion, with organic revenue growth estimated at 6.1 to 7.7 percent.
Analysts surveyed by Thomson Reuters had projected earnings of $13.04 per share and a revenue increase of 4.4 percent, estimating total revenues to be around $20.23 billion. These analyst estimates typically exclude special items.
